2024-11-14 08:30
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Message from the CEO This quarter, IBT completed the global Phase 3 clinical trial “The Connection Study” for the drug candidate IBP-9414...
2024-10-23 09:00
Infant Bacterial Therapeutics to present at FDA workshop in the USA
Infant Bacterial Therapeutics has been invited to present at the event “Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very...
2024-10-09 09:00
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2025
The 2024 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
2024-09-01 19:27
IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.
The following topics are planned to be commented on during the call: Join the video meeting by clicking this link: https://meet.google.com/jmy-cdhn-wwo.You...
2024-08-30 18:38
IBT's phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality
IBT has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug...
Message from the CEO IBT has announced the crucial results from the global clinical phase 3 study “The Connection Study” for our drug project...
Infant Bacterial Therapeutics AB (IBT) announces today that it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO)...
2024-07-08 16:40
“The Connection Study” is completed
The last patient in IBT’s global phase 3 clinical program “The Connection Study” has finished treatment. IBP-9414 is being developed...
2024-05-08 18:11
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved: ContactsStaffan...
Message from the CEO IBT has successfully completed the recruitment of infants for our Phase III study (The Connection Study), which is the final clinical...